The Combination of Three Components Derived from Sheng MaiSan Protects Myocardial Ischemic Diseases and Inhibits Oxidative Stress via Modulating MAPKs and JAK2-STAT3 Signaling Pathways Based on Bioinformatics Approach by Fang Li et al.
fphar-08-00021 January 31, 2017 Time: 11:15 # 1
ORIGINAL RESEARCH
published: 31 January 2017
doi: 10.3389/fphar.2017.00021
Edited by:
Chrishan S. Samuel,
Monash University, Australia
Reviewed by:
Huang-Tian Yang,
Shanghai Jiao Tong University, China
Sandra Sigala,
University of Brescia, Italy
*Correspondence:
Junping Kou
junpingkou@cpu.edu.cn
Boyang Yu
boyangyu59@163.com
Specialty section:
This article was submitted to
Cardiovascular and Smooth Muscle
Pharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 25 August 2016
Accepted: 11 January 2017
Published: 31 January 2017
Citation:
Li F, Zhang Y, Zeng D, Xia Y, Fan X,
Tan Y, Kou J and Yu B (2017)
The Combination of Three
Components Derived from Sheng
MaiSan Protects Myocardial Ischemic
Diseases and Inhibits Oxidative Stress
via Modulating MAPKs
and JAK2-STAT3 Signaling Pathways
Based on Bioinformatics Approach.
Front. Pharmacol. 8:21.
doi: 10.3389/fphar.2017.00021
The Combination of Three
Components Derived from Sheng
MaiSan Protects Myocardial
Ischemic Diseases and Inhibits
Oxidative Stress via Modulating
MAPKs and JAK2-STAT3 Signaling
Pathways Based on Bioinformatics
Approach
Fang Li, Yu Zhang, Donglin Zeng, Yu Xia, Xiaoxue Fan, Yisha Tan, Junping Kou* and
Boyang Yu*
Jiangsu Key Laboratory of TCM Evaluation and Translational Research, Department of Complex Prescription of Traditional
Chinese Medicine, China Pharmaceutical University, Nanjing, China
GRS is a drug combination of three components including ginsenoside Rb1, ruscogenin
and schisandrin. It derived from the well-known TCM formula Sheng MaiSan, a widely
used traditional Chinese medicine for the treatment of cardiovascular diseases in clinic.
The present study illuminates its underlying mechanisms against myocardial ischemic
diseases based on the combined methods of bioinformatic prediction and experimental
verification. A protein database was established through constructing the drug-protein
network. And the target-pathway interaction network clustered the potential signaling
pathways and targets of GRS in treatment of myocardial ischemic diseases. Several
target proteins, such as NFKB1, STAT3 and MAPK14, were identified as the candidate
key proteins, and MAPKs and JAK-STAT signaling pathway were suggested as the
most related pathways, which were in accordance with the gene ontology analysis.
Then, the predictive results were further validated and we found that GRS treatment
alleviated hypoxia/reoxygenation (H/R)-induced cardiomyocytes injury via suppression
of MDA levels and ROS generation, and potential mechanisms might related to the
suppression of activation of MAPKs and JAK2-STAT3 signaling pathways. Conclusively,
our results offer the evidence that GRS attenuates myocardial ischemia injury via
regulating oxidative stress and MAPKs and JAK2-STAT3 signaling pathways, which
supplied some new insights for its prevention and treatment of myocardial ischemia
diseases.
Keywords: Sheng MaiSan, GRS, bioinformatics approach, myocardial ischemic diseases, oxidative stress,
MAPKs signaling pathway, JAK-STAT signaling pathway
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INTRODUCTION
Myocardial ischemic disease is a public health concern with an
increasing incidence that results in high morbidity and mortality
worldwide (Yellon and Hausenloy, 2007). The therapeutic
methods targeted at recovering blood flow to the ischemic
myocardium are frequently applied in clinic. However, the
process of reperfusion might trigger additional injury, as
evidenced by an extension of the infarct size (Matsumura
et al., 1998). It is well-known that oxidative stress is one of
the main pathological factors of myocardial ischemic diseases
(Lakshmi et al., 2009). Oxidative stress mediators, such as ROS
release with high concentrations, could inhibit cell proliferation,
augment myocardial apoptosis and increase infarct size, which
significantly contribute to long-term mortality and chronic heart
failure (Stanciu et al., 2000). Thus, exploring anti-oxidative stress
agents is a therapeutic opportunity for ischemia diseases.
Disease state is considered as a systemic imbalance in the
theory of traditional Chinese medicine (TCM), and TCM could
adjust systemic imbalance through the network system of
active components aiming at multiple pathways and targets (Li
et al., 2007). TCM are drawing increased notice owing to their
clinical curative efficacy for a long time. However, the obscure
molecular mechanisms impeded their further development.
Nowadays, the constant development of network pharmacology
and improvement of biological network data have facilitated
system level understanding of the interactions of genes, proteins,
thus providing the novel approaches for illuminating the
underlying mechanisms associated with the therapeutic efficacy
of the active components of TCM (Li et al., 2011; Mei et al.,
2012).
Network pharmacology could exert an influence at several
respects in target and pathway identification and drug-target
interactions illumination. Many literatures have successfully
reported significant biological findings from these networks.
Drug-target correlation networks are usually employed to
interpret the mechanism of drug’s action (Gu et al., 2011).
Meanwhile, the protein-disease and drug-drug network were also
used to find out the relevance between the target proteins and
diseases (Jiang et al., 2013). The theoretical algorithm named
as CIPHER has been applied to discern the key targets and
pathways (Wu et al., 2008). Network pharmacology has become
the foundation stone for the elucidation of drugs’ mechanisms.
Detecting the latent critical targets and signaling pathways for
TCM against the diseases via bioinformatic approaches is time
saving and efficient.
Sheng MaiSan is a famous traditional Chinese formula for
the treatment of cardiovascular diseases in clinic (Zhang et al.,
2008). Many main kinds of chemical ingredients, such as
ginsenosides, homoisoflavonoids and lignans, have been reported
to be responsible for the pharmacological activities of Sheng
MaiSan (Wang et al., 2011). Developing a new type of modern
drug combination with clear ingredients and controllable quality
will be the new direction of TCM research. Meanwhile, it
plays an essential role in speeding up the modernization and
internationalization of TCM (Li et al., 2008). Recently, we
screened a new drug combination (GRS, the proportion as
6:0.75:6) comprising three compounds, including ginsenoside
Rb1 (Ginsenosides of Red ginseng-G), ruscogenin (Saponins of
Radix ophiopogonis-R), and schisandrin (Lignans of Fructus
schisandrae-S), which showed a significant cardioprotective
effects in experimental studies (Kou et al., 2014). The proportion
of the combination was optimized to achieve the highest efficacy,
quality stabilization and clinical safety for research (Chu, 2014).
However, the action mode and related signaling pathways against
myocardial ischemic diseases of GRS are unknown. Network
pharmacology could accelerate the comprehension and predict
the potential critical targets and pathways, and the forecasting
consequences might provide some clues for further experimental
validation.
Therefore, to better understand how the combination GRS
affects biological processes, the bioinformatic approach was
implemented to illuminate the correlation of the targets and
pathways of GRS. The active ingredients in combination
GRS targeted numerous essential proteins with a high
degree of specificity and with functional contributions to
the main signaling pathways at the same time, which led to
the new equilibrium of biological system against diseases.
Then, the partial predictive results were verified in H9c2
cardiomyocytes stimulated by hypoxia/reoxygenation (H/R).
H9c2 rat cardiomyocyte cell line have been widely used as
a model for investigation of myocardial ischemic diseases
(Zordoky and El-Kadi, 2007; Chou et al., 2010). And we
induced injury by H/R, which is more physiologically relevant
to mimic ischemia/reperfusion injury to cardiomyocytes in vivo
(Shin et al., 2009). Our results will shed new light on the
pharmacological mechanism of the combination derived from
Sheng MaiSan and will facilitate an illustration of the detailed
mechanisms of myocardial ischemic diseases in the network
context, and lay the foundation for the further development of
new drug with independent intellectual property.
MATERIALS AND METHODS
Drugs and Reagents
GRS was a mixture of ginsenoside Rb1, ruscogenin and
schisandrin (6:0.75:6). Schisandrin and ginsenoside Rb1 were
obtained from Zelang Bio-Technology Co., Ltd (Nanjing, China).
Ruscogenin was seperated in the laboratory and the purity
was higher than 99%. Fetal bovine serum (FBS) was received
from ScienCell (Carlsbad, CA, USA). Dulbecco’s modified
Eagle medium (DMEM) was purchased from GIBCO/BRL (Life
Technologies, Carlsbad, CA, USA). N-acetyl cysteine (NAC) was
purchased from Sigma-Aldrich (St. Louis, MO, USA). 3-[4,5-
Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)
was purchased from AMRESCO (Cleveland, OH, USA). The
kits for determination of lactate dehydrogenase (LDH), the
malondialdehyde (MDA) and the fluorescent kit for 2′, 7′-
dichlorofluorescein diacetate (DCFH-DA) were obtained from
Beyotime Institute of Biotechnology (Shanghai, China). Protease
inhibitor, RIPA lysis buffer, and enhanced chemiluminescene
(ECL) reagent were obtained from Vazyme Biotech (Nanjing,
China). Antibody against GAPDH was purchased from Bioworld
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Technology (St. Louis Park, MN, USA), antibody against JNK,
p-JNK, p38, p-p38, ERK1/2, p-ERK1/2 and Jak2, p-Jak2, Stat3,
p-Stat3 were obtained from Cell Signaling Technology (Boston,
MA, USA).
Construction of the Protein Database
As reported in our previous studies (Tan et al., 2014; Li F.
et al., 2015), the protein database was composed of two parts.
Figure 1A depicts the process of this study. The first part of
the database was composed of the known targets, which were
retrieved from the literature database1. The search Mesh terms
were assigned as “compound name” (#1 “ginsenoside Rb1,” #2
1http://www.ncbi.nlm.nih.gov/pubmed/
ruscogenin, #3 schizandrin, #4 #1 NOT #2 NOT #3, #5 #1
OR #2 OR #3). The proteins/genes which accorded with the
Mesh terms were collected from the literatures2. The second
part consisted the novel proteins related to the compounds
with high affinity, which obtained from the PharmMapper
database3 (Liu et al., 2010). Structures of the three components
were established by Sybyl 6.9, and then were employed to all
hydrogens and Gastiger-Huckel charges in Sybyl 6.9 in the
Tripos force field in an implicit solvent condition (Li F. et al.,
2015). The minimization steps included 1000 cycles of steepest
descent until meeting convergent threshold of 0.05 kal-1Å-1 (Tan
2http://www.ncbi.nlm.nih.gov/mesh/
3http://59.78.96.61/pharmmapper/
FIGURE 1 | Drug–target interaction network. (A) The flowchart of model establishing. (B) Myocardial ischemic diseases related proteins information statistics.
(C) The drug–target network of GRS. The red diamond represents ginsenoside Rb1; the yellow triangle represents schisandrin; the green square represents
ruscogenin. (D) Compound-Myocardial ischemic diseases related protein network. The red diamond represents ginsenoside Rb1; the blue triangle represents
schisandrin; the green square represents ruscogenin.
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et al., 2014). Then the three compounds were imported into
the PharmMapper human protein database, and the top 100
proteins were chosen. Meanwhile, the combined proteins/genes
contained in the results were screened with the myocardial
ischemic diseases from the OMIM, Genecards and DrugBank
database. Protein–protein/gene–gene information included links
to databases, such as BIND, BioGRID, DIP, HPRD, IntAct and
MINT, which represented the major interactome for further
bioinformatics analysis. The proteins/gene/GEO Profiles were
standardized in the NCBI database entailed on Homo sapiens4.
The Establishment and Analysis of the
Network
The drug-target network was constructed using Cytoscape 2.8.3
(Cline et al., 2007). Nodes in the interactome corresponding
to the genes and edges represented documented interactions
in the visualization. Cytoscape could be download from the
website http://cytoscape.org. Then the degree and betweenness
of the ingredients were analyzed with the Centiscape module
in Cytoscape. The most fundamental feature of the node was
its degree, which showed how many links the node with other
4http://www.ncbi.nlm.nih.gov/geoprofies/
nodes. The betweenness and the degree were the node topological
and centric indexes (Huang et al., 2009a; Li F. et al., 2015).
Higher degree and larger betweenness nodes are most significant
(Barabasi and Oltvai, 2004; Opsahl et al., 2010).
Network analysis was then subjected to GeneMANIA
in Cytoscape, a plugin used for making fast and efficient
gene function predictions. GeneMANIA algorithms have been
exhibited to be as well as, or better than, in accuracy and
speed compared with other gene function prediction algorithms.
Furthermore, the GeneMANIA plugin was developed for the
consideration and visualization of pathway interaction networks
among the genes. The Homo sapiens database of GeneMANIA
was previously downloaded from the internet, and then gene
names were imported into the plugin, followed by selecting the
right names and descriptions for them. Finally, the visualization
network was represented as the pathway between the interaction
genes.
On account of the high degree nodes from drug-target
network, the proteins with little biological meanings in functional
annotation chart through Biocarta analysis were eliminated
(Huang et al., 2009b). Pathway analysis plays a vital part in
detecting potential biological processes that the genes participate
in. A variety of databases such as GeneGo, KEGG and Biocarta
TABLE 1 | The general network properties of the drug-target interaction network.
Number of nodes Number of edges Average number of neighbors Network centralization Characteristic path length Network heterogeneity
268 373 2.784 0.725 2.582 5.250
FIGURE 2 | The analysis of interaction network. (A) The protein–protein interaction network. (B) The relationship between node betweenness and degree
distribution.
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collect cured pathways (Apic et al., 2005). In our current study,
the functional annotation clusters were divided into groups of
similar annotations employing Biocarta functional annotation
tool in accordance with the enrichment scores. Gene ontology
(GO), another form of pathway, displays the cellular locations
and physiological functions of multiple genes (Huang et al.,
2009b). GO analysis were proceeded using the BINGO 2.4.4
plugin of Cytoscape 2.8.3. The genes were applied to cellular
component; molecular function and biological process ontology
file analysis.
Cardiomyocytes Culture
Rat H9c2 cardiomyocytes was purchased from Shanghai Institute
of Cell Biology, Chinese Academy of Sciences (Shanghai, China).
The cells were grown in DMEM added with 10% FBS, 100 µg/mL
streptomycin and 100 U/mL penicillin at 37◦C in a humidified
atmosphere containing 5% CO2.
H/R Injury Model In vitro
The oxygen and glucose deprived (OGD) technique was
established according to a previously described protocol (Rizvi
et al., 2010). In current investigation, the OGD injury was
conducted through supplementing none glucose DMEM and
exposed to a hypoxic condition of 94% N2, 5% CO2 and
1% O2 at 37◦C in a humidified N2/CO2 incubator and then
in a standard incubator with normal atmosphere at 37◦C.
H9c2 cardiomyocytes were given with GRS (0.1–10 µg/mL) or
N-acetyl cysteine (NAC, 500 µmol/L) during the hypoxia. At the
beginning of reoxygenation, H9c2 cells were re-exposed to GRS
and NAC.
Cell Viability Assay and Measurement of
LDH Activity
H9c2 cardiomyocytes growing exponentially were trypsinized
and then approximately 8000 cells/well were seeded into 96-well
plates. After the experimental treatment, cells were given with
0.5 mg/mL MTT for 3 h at 37◦C. And then the medium was
discarded and the formazan crystals was dissolved with DMSO.
The absorbance was read at 570 nm with a reference wavelength
of 650 nm. The LDH activity was then detected to further
investigate the degree of cell injury. At the end of the experiment,
the supernatants of culture medium were gathered. The LDH
activity was measured at 490 nm following the manufacturer’s
descriptions.
Measurement of Malondialdehyde (MDA)
and Intracellular ROS
The content of MDA was determined with assay kits according
to the manufacturer’s instructions. In brief, cells were harvested
by trypsinization and cellular extracts were lysed with RIPA lysis
buffer. Then lysed cells were centrifuged and the supernatant
were subjected to the measurement of MDA levels and
the protein contents. MDA contents were normalized to
milligram protein. Additionally, ROS levels were detected
using 2′, 7′-dichlorofluorescein diacetate (DCFH-DA).
The cardiomyocytes were first incubated with DCFH-DA
(10 µmol/L) for 30 min, then washed with PBS and visualized by
fluorescence microscopy.
Western Blot Analysis
As reported (Guan et al., 2013), the H9c2 cardiomyocytes were
lysed with RIPA lysis buffer added with protease inhibitor. The
cell lysates were then centrifuged and protein concentrations
were calculated using a BCA protein assay kit (Beyotime Institute
of Biotechnology, Shanghai, China). The equal amounts of
protein (40 µg) were separated by denaturing 12.5% SDS-
PAGE and transferred onto PVDF membranes. The membranes
were then blocked with 3% BSA and incubated with primary
antibodies against JNK, p-JNK, p38, p-p38, ERK1/2, p-ERK1/2,
Jak2, p-Jak2, Stat3, p-Stat3 and GAPDH (dilution 1:1000, 1:800,
1:1000, 1:800, 1:1000, 1:1000, 1:1000, 1:500, 1:1000, 1:500, 1:8000,
respectively) overnight at 4◦C. Then membranes were probed
with peroxidase conjugated secondary antibody with a 1: 8000
dilution. The antigen-antibody complexes were then tested with
ECL reagent and visualized by ChemiDocTM MP System (Bio-
Rad), and analyzed using Image LabTM Software (version 4.1,
Bio-Rad).
TABLE 2 | Proteins information of high degree connection and correlation.
Gene symbol Betweenness Degree
NFKB1 1643.686 193
JUN 1125.209 207
EGF 1010.55 79
STAT3 976.7627 160
CDH5 778.7818 104
HIF1A 775.6348 120
FOS 767.6101 167
TNF 738.1665 115
APP 731.193 91
ESR1 728.0267 112
MAPK14 697.1574 142
SLC2A1 672.8005 67
TP53 660.8239 128
MAPK8 622.0975 126
SRC 604.3359 94
HSP90AA1 581.0109 109
PRL 580.4675 52
CSF3 562.9149 82
CD14 548.6541 88
MAPK1 537.9401 120
MAPK3 523.9574 109
ITGB2 506.0382 103
MMP9 505.1719 93
ATF3 500.4878 101
AKT1 494.9877 114
IL6 494.3673 120
CAV1 486.5094 113
EGR1 484.6549 114
IL8 482.2064 129
NFKBIA 458.8095 125
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FIGURE 3 | Statistical analysis of gene ontology metadata. Statistical analysis of the gene ontology classification was performed using the BiNGO plugin in
cytoscape. The left picture is a graphical representation of top 5 scored -lg (P-value) significantly enriched ontologies, presented as the cellular component (A),
molecular function (B) and biological process (C). The right picture is the enlarged figures including different numbers of top ontologies in the analysis. The
orange-marked ontologies in the left are contained in the corresponding right figures.
Statistical Analysis
All experiments were performed in triplicate and the
data are expressed as the mean ± SEM. Student’s two-
tailed t-test for comparison between two groups and
one-way analysis of variance (ANOVA) were employed
for statistical analysis. Dunnett’s test was applied when
the data involved more groups. P < 0.05 was defined as
significant.
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TABLE 3 | The representive signaling pathways for annotation cluster of
GRS.
Annotation cluster Signaling pathway
hsa04010 MAPK signaling pathway
hsa04210 Apoptosis
hsa04620 Toll-like receptor signaling pathway
hsa05010 Alzheimer’s disease related pathway
hsa05050 Dentatorubro pallidoluysian atrophy
hsa04060 Cytokine–cytokine receptor interaction
hsa05030 Amyotrophic lateral sclerosis
hsa04910 Insulin signaling pathway
hsa04630 JAK-STAT signaling pathway
hsa04510 Focal adhesion
FIGURE 4 | The pathway enrichment analysis. The Bayes factor
quantifying the amount of evidence supporting the hypothesis that the
annotation is associated with your gene list. The negative logarithm of the
p-value calculated from the Bayes factor, calculated using a Fisher’s exact
test.
RESULTS
Drug-Target Interaction Network
The characteristics of the drug-target network were shown in
Figure 1B and Table 1. Then, we constructed the network
of potential targets of the components in GRS by cytoscape,
as shown in Figure 1C. Further, we excluded little biological
meaning proteins with Biocarta functional annotation analysis.
According to the correlation between proteins with biological
meaning, we re-built the protein targets network related to
myocardial ischemic diseases of the combination GRS, as
illustrated in Figure 1D. Obviously, the drug-target network
was dense and the combination GRS targeted a great deal of
proteins. Moreover, the drug-target network results displayed
that a single component could act on multiple proteins, while
different composition could play a role in the same protein. The
link between each component and proteins, protein and protein
are close, and the overall correlations are evenly distributed.
Evaluation of the Important Proteins
Through the information technology analysis and forecast of
the relationship between protein and protein, we constructed
the protein–protein interaction network of the combination
targets related with myocardial ischemic disease (Figure 2A).
Then, we selected the essential proteins which have the higher
connection degree and larger betweenness from the network
(Figure 2B) for becoming the candidate key proteins, such as
NFKB1, JUN, EGF, STAT3, CDH5, HIF1A, FOS, TNF, APP,
ESR1, MAPK14, SLC2A1, TP53, MAPK8, all of which were
associated with MAPKs, JAK-STAT, oxidative stress and NF-
κB signaling pathways and so on (Table 2). Furthermore, we
found the protein, which was significantly enriched by analysis
of genetic background of the protein in the network, such as
STAT3 acceptor, MAP kinase and JNK kinase. The graphical
representations of the relative positions of the terms in the
GO hierarchy were displayed in Figures 3A–C, with the extent
of importance showed according to color. The major cellular
component ontologies (Figure 3A) were cytoplasmic part,
plasma membrane, membrane-bounded organelle, intracellular
organelle and interleukin-6 receptor complex. The terms
such as regulation of apoptosis, regulation of MAP kinase,
inflammatory response, regulation of phosphorylation and
regulation of JAK-STAT cascade were significantly enriched in
the molecular function ontologies (Figure 3B). In addition,
the enriched biological process ontologies were managed by
cytokine receptor binding, stat3 receptor activity, MAP kinase
activity, as well as oxidoreductase activity and JUN kinase activity
(Figure 3C).
The Pathway Enrichment Analysis
The top 10 main functional annotation clusters were displayed
in Table 3 and Figure 4 ranked by the Biocarta functional
annotation cluster tool. The functional annotation cluster
divided the categories of similar annotations following
their enrichment scores. The relevant protein terms in
the highest scored cluster were related with the MAPK
signaling pathway. The second main pathways related to
apoptosis. And the rest clusters on comprised pathways related
to Toll-like receptor, Alzheimer’s diseases, Dentatorubro
pallidoluysian atrophy, Cytokine–cytokine receptor interaction,
Amyotrophic lateral sclerosis, Insulin, JAK-STAT and Focal
adhesion signaling pathways. On the basis of the enrichment
scores, the MAPK signaling pathway was the most possible
candidate for GRS function aiming at myocardial ischemic
diseases.
Experimental Validation
We first examined the effects of different condition of H/R
injury on H9c2 cardiomyocytes viability. As shown in Figure 5A,
hypoxia caused a time-dependent decrease in cell viability. Then,
the cells were exposed to hypoxia for 6 h, followed by different
times of reoxygenation. Adequate cell injury extent was observed
at 6 h of reoxygenation (Figure 5B). Moreover, we detected the
viability of cardiomyocytes after the treatment with GRS and GRS
at concentrations of 0.1–60 µg/mL did not markedly influence
cardiomyocytes viability (Figure 5C). Then three concentrations
(0.1, 1 and 10 µg/mL) were chosen for further detection. H9c2
cardiomyocytes exposed to H/R (H 6 h/R 6 h) led to a decrease
in cell viability, while given with 0.1–10 µg/mL GRS and 500 µM
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FIGURE 5 | Effects of GRS on H/R induced H9c2 cardiomyocytes injury. H9c2 cardiomyocytes were exposed to hypoxia followed by reoxygenation. Then the
cell viability was detected by the MTT assay described in method. (A) Effect of hypoxia on H9c2 cell viability. (B) Effect of reoxygenation on H9c2 cell viability.
(C) Effect of GRS on H9c2 cell viability. (D) H9c2 cells were treated with GRS followed by H/R and cell viability was determined by MTT assay. Results were obtained
from three independent experiments and were presented as mean ± SEM. #P < 0.05, ##P < 0.01 vs. control group without H/R, ∗P < 0.05, ∗∗P < 0.01 vs. group
treated with H/R alone.
positive control drug NAC maintained cell viability (Figure 5D).
As LDH release was an accepted sign for cell injury, the release of
LDH in culture medium was determined. LDH release markedly
increased after H/R injury as compared to control group, whereas
treatment with 0.1–10 µg/mL GRS and 500 µM NAC markedly
inhibited the release of LDH (Figure 6A). These results indicated
that GRS had an obvious protective effect against H/R-mediated
damage in H9c2 cardiomyocytes.
As a significant product of lipid peroxidation, MDA indirectly
reveals the generation of intracellular ROS. When cells were
subjected to H/R injury, the content of MDA increased
remarkably. Whereas, the concentration of MDA significantly
decreased after treatment with 0.1–10 µg/mL GRS and 500 µM
NAC (Figure 6B). Meanwhile, compared to the control group,
ROS production was markedly increased in the H/R group. While
cells treated with GRS showed a substantial reduction in ROS
levels (Figure 6C).
As shown in Figure 7, we evaluated whether GRS regulated
the MAPKs signaling pathway to validate the results from the
target-pathway interaction network analysis. The Western
blotting results revealed that H/R injury significantly
increased phosphorylation of JNK, p38 and ERK1/2 in
H9c2 cardiomyocytes, indicating that H/R injury activated
MAPKs pathway. While 1–10 µg/mL GRS could down-regulate
phosphorylation of JNK, p38 and ERK1/2, and there was no
difference in total JNK, p38 and ERK1/2 protein abundance
among all groups detected.
In addition, we further investigated whether GRS could
regulate the JAK-STAT signaling pathway. As shown in Figure 8,
we found that GRS at the concentration of 10 µg/mL could
inhibit the phosphorylation of JAK2 and STAT3 under H/R
conditions, suggesting that GRS might play a role in protecting
myocardial ischemia injury through the inactivation of JAK2-
STAT3 signaling pathway.
DISCUSSION
Reperfusion-induced oxidative stress is a key contributor to
myocardial ischemia-reperfusion (MI/R) injury by inducing
a cascade of pathological changes, such as DNA damage,
mitochondrial dysfunction and protein aggregation, which in
turn lead to cardiomyocytes apoptosis (Sinha et al., 2013).
MI/R-induced redox aberrance results from excessive ROS
generation and antioxidant system impairment (Chinda et al.,
2013). Disrupt balance between oxidants and antioxidants
lead to uncontrolled myocardial injury. Our study provided
evidence that the combination GRS inhibited H/R-induced
H9c2 cardiomyocytes injury via potent antioxidant effect as
inferred by reduced MDA levels and ROS generation. Whereas,
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FIGURE 6 | Effects of GRS on LDH release (A), MDA content (B) and intracellular ROS (C) in H9c2 cardiomyocytes subjected to H/R injury. H9c2
cardiomyocytes were treated with GRS at the concentration of 0.1–10 µg/mL and then exposed to hypoxia of 6 h followed by 6 h reoxygenation. LDH release and
MDA content were measured by assay kit. ROS levels were determined using 2′, 7′-dichlorofluorescein diacetate (DCFH-DA, Molecular Probes). NAC was used as a
positive control drug. Results were obtained from three independent experiments and were presented as mean ± SEM. ##P < 0.01 vs. control group without H/R,
∗P < 0.05, ∗∗P < 0.01 vs. group treated with H/R alone.
the especial pathway and potential mechanisms has yet to be
explored.
As we all know, the complexity of components and obscure
mechanisms hinder the development and internationality of
TCM in the world. In recent years, network pharmacology has
provided an efficient approach for the underlying molecular
mechanisms elucidation of TCM. We applied the network
of drug-target and target-pathway interaction to discover
the potential targets and pathways of the combination of
three bioactive components derived from Sheng MaiSan to
decipher its mechanism in the treatment of myocardial ischemic
diseases.
We found that 30 of nodes with high-degree were existed in
the highest annotation cluster pathway. Many pharmacological
investigations exhibited that the transcription factor NF-
κB exerts an essential part in cell proliferation and serves
as an important modulator of the inflammatory process.
The activity suppression of NF-κB could protect myocardial
ischemia reperfusion induced heart injury (Liang et al., 2014).
STAT3 has been indicated to be essential for cardioprotective
effects such as preservation of LV functional reserve and
perfused capillary density, decrease of apoptotic cell death
and reduction of infarct size (Smith et al., 2004). Moreover,
MAPK participated in the regulation of cellular responses to
a variety of stimuli, such as mitogens and pro-inflammatory
cytokines. Mitogen-activated protein kinases 3, 8 and 14
regulate proliferation, gene expression, cell survival, apoptosis
and many other cell functions (Pearson et al., 2001; Li G.
et al., 2015). The function mechanism of these important
proteins might be that they influence the integral network
instead of one target alone. The overall network would be
disrupt in a pathological state once the critical targets are
pulled out from the network. On the contrary, the pathological
condition would become normal when very critical proteins
aimed at.
Gene ontology has been extensively employed to
interpret gene products in any organism as the ontology
for designating structural controlled vocabulary terms (Li
F. et al., 2015). And GO is composed of three separate
ontologies, including cellular component, molecular
function and biological process, which describe the
attributes of gene products or gene product group.
The three annotation levels were in accordance with
signal pathways existed in the functional annotation
clusters, which were correlated with the regulation
of MAP kinase and the JAK-SATA cascade. This
elucidated the action mechanism from the perspective
of GO.
Biocarta functional annotation tool was applied to group
the functional annotation clusters with similar annotations
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FIGURE 7 | Effects of GRS on MAPKs signaling pathway in H/R induced H9c2 cardiomyocytes. H9c2 cardiomyocytes were treated with GRS at the
concentration of 0.1–10 µg/mL and then exposed to hypoxia of 6 h followed by 2 h reoxygenation. Protein expressions were detected by western blot. (A) Protein
expressions of JNK and p-JNK using GAPDH as the loading control. (B) Protein expressions of p38 and p-p38 using GAPDH as the loading control. (C) Protein
expressions of ERK1/2 and p-ERK1/2 using GAPDH as the loading control. Results were obtained from three independent experiments and were presented as
mean ± SEM. ##P < 0.01 vs. control group without H/R, ∗P < 0.05, ∗∗P < 0.01 vs. group treated with H/R alone.
on the basis of the enrichment scores. The proteins in each
groups would be in high relevance with each other. The
most essential protein terms in the topmost scored cluster
are correlated with the MAPKs signal pathway. Intracellular
MAPK (mitogen-activated protein kinase) signaling cascades
exert an important part in the pathogenesis of cardiovascular
diseases (Suchal et al., 2016). MAPKs are divided into three
subgroups in general: p42/p44 extracellular signal-related
kinases (ERK1/2), p38 MAPK, and c-Jun N-terminal protein
kinase (JNK) (Muslin, 2008). Reactive oxygen species generated
due to ischemia-reperfusion injury could activate MAPKs
signaling pathways (Gao et al., 2015). When MAPKs were
activated, a variety of different substrate proteins were
phosphorylated, including essential modulatory enzymes,
apoptosis factors and cytoskeletal proteins, through influencing
the phosphorylation state of the substrate proteins (Zhou et al.,
2002).
Myocardial ischemia injury activated p38 MAPK, with
the transcription factors and protein phosphorylation,
increasing adhesion molecule expression and granulocyte
activation, eventually leading to myocardial necrosis and
apoptosis of large area (Ma et al., 1999). Meanwhile, the oxide
Frontiers in Pharmacology | www.frontiersin.org 10 January 2017 | Volume 8 | Article 21
fphar-08-00021 January 31, 2017 Time: 11:15 # 11
Li et al. Combination Protects Myocardial Ischemic Diseases
FIGURE 8 | Effects of GRS on Jak-Stat signaling pathway in H/R induced H9c2 cardiomyocytes. H9c2 cardiomyocytes were treated with GRS at the
concentration of 0.1–10 µg/mL and then exposed to hypoxia of 6 h followed by 2 h reoxygenation. Protein expressions were detected by western blot. (A) Protein
expressions of Jak2 and p-Jak2 using GAPDH as the loading control. (B) Protein expressions of Stat3 and p-Stat3 using GAPDH as the loading control. Results
were obtained from three independent experiments and were presented as mean ± SEM. #P < 0.05, ##P < 0.01 vs. control group without H/R, ∗P < 0.05,
∗∗P < 0.01 vs. group treated with H/R alone.
produced by reperfusion injury could result in JNK MAPK
activation, and then activate a variety of transcription factors
and trigger programmed cell death (Ferrandi et al., 2004).
Various studies have demonstrated that targeted inhibition
of p38/JNK protect the myocardium from ischemia and
reperfusion injury by reducing oxidative stress, inflammation,
cardiomyocyte apoptosis, metabolic abnormalities and by
maintaining cytoskeletal architecture (Li et al., 2014; Gao
et al., 2015). In general, the ERK cascade is regarded to
participate both cell proliferation and survival. Studies had
previously demonstrated that activation of ERK1/2 at the time
of myocardial reperfusion confer powerful cardioprotection,
indicating a potential amenable pharmacological target for
cardioprotection (Armstrong, 2004). While latest investigations
have verified that, the persistent activation of ERK is also
participated in the process of apoptosis (Plotkin et al., 2005;
Sun et al., 2012). GRS might produced an interlinked network,
thus, these building blocks of the body could exert effect as
a whole. In the current research, we detected the efficacy of
GRS on the expression and activation of MAPKs signaling
pathway in H/R-induced H9c2 cardiomyocytes, confirming
the forecasting consequences and offering an illustration of the
molecular mechanisms of myocardial ischemia diseases. As an
active component of GRS, ginsenoside Rb1 has been reported to
alleviate the ischemia-reperfusion injury through the inhibition
of p38 MAPK and JNK MAPK (Li et al., 2012, Li G. et al.,
2015). We found that ruscogenin suppressed mouse neutrophil
activation through the inhibited phosphorylation of p38 MAPK,
ERK1/2 and JNK (Lin et al., 2015). Schisandrin could also exert
anti-inflammatory effects via inhibition of JNK and p38 MAPK
activities in a RAW 264.7 macrophage cell line (Guo et al.,
2008).
Due to the large number of literatures with the correlation
between the three components in combination GRS and
MAPKs signaling pathway, thus, we further investigate whether
the combination GRS derived from Sheng MaiSan exerts
cardioprotective effects through other novel signaling pathway.
Then we focused on the Janus kinase (JAK)-signal transducers
and activators of transcription (STAT) signaling pathway based
on the former predicted results. JAK-STAT pathway is a stress-
responsive mechanism that delivers signals from the cell surface
to the nucleus, hence, regulating gene expression, which plays an
essential role in the mechanism of heart diseases with mediating
myocardial cell growth, survival and apoptosis (Bolli et al., 2003).
Latest researches have illustrated that ischemia and reperfusion
injury in myocardium lead to quick activation of this pathway
and activation intervention of this pathway induces the recovery
in cardiac function (Mascareno et al., 2001). JAK2 and STAT3
are central component of cardioprotection (Bolli et al., 2011).
In our study, we observed that GRS could markedly inhibit the
activation of JAK2-STAT3 signaling pathway. The JAK-STAT
signaling pathway is significant for cytokine receptor signaling
associated with inflammatory responses. Our investigations
demonstrate that the activation of the JAK2-STAT3 signal
pathway is possible involved in the emergence and progression
of systemic inflammatory response. Therefore, the activation
inhibition of JAK2-STAT3 signaling pathways might due to
the reduction of inflammatory response. Moreover, the drugs
might exerted different effects in different detecting time points
and further investigations are needed to explore the underlying
protection mechanism in depth. To the best of our knowledge,
this is the first study, which illustrates that the regulation of the
JAK2-STAT3 pathway exerts a vital part in the pharmacological
action of GRS.
Frontiers in Pharmacology | www.frontiersin.org 11 January 2017 | Volume 8 | Article 21
fphar-08-00021 January 31, 2017 Time: 11:15 # 12
Li et al. Combination Protects Myocardial Ischemic Diseases
CONCLUSION
The combination of three components derived from Sheng
MaiSan appears effective in mitigating H/R-induced H9c2
cardiomyocytes injury via suppression of oxidative stress.
Then we applied bioinformatics approach to predict the
potential molecular mechanisms of the combination GRS
against myocardial ischemia diseases based on an integrated
target-pathway interaction network. According to this network,
we constructed the molecular targets and signaling pathways
correlations between bioactive components and myocardial
ischemia diseases. Then we confirmed partial results through
experiments in cell model. These outcomes illustrated that
the bioinformatics methods were effective in predicting and
illuminating the interaction between drug actions and complex
diseases. Due to these combined methods, the MAPKs and JAK2-
STAT3 signaling pathways were discerned and validated to exert
an significant part in the combination GRS mechanism against
myocardial ischemia diseases. Further investigations need to
proceed more researches of the efficacy of active components on
other signaling pathways and their interactions. In addition, the
H9c2 rat cardiomyocytes used in our research could not precisely
represent cardiac myocytes though it was extensively used in
the investigation of cardiovascular diseases. And application of
primary cultured cardiac myocyte is in progress to sustain the
cardioprotective effect of GRS.
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